CD38 and CD157: biological observations to clinical therapeutic targets.
The application of molecular knowledge for developing new medical technologies is the goal of molecular medicine. Success in this area is highly dependent on the interaction of investigators from fields as diverse as biochemistry, cell biology, immunology, physiology, epidemiology, and physics, with an eye toward applying their insights and discoveries to improving human health. Such interdisciplinary approaches rarely find the common ground and language necessary to achieve this goal. Recently, a meeting of researchers studying the ectoenzymes CD38 and CD157 brought together insights into the regulation of calcium signaling, the metabolism of pyridine nucleotides by CD38 and CD157, and subsequent effects on immune function. Together, these discoveries were being applied to the development of novel therapeutics and diagnostics for myeloma and chronic lymphocytic leukemia. This issue of Molecular Medicine, featuring several short reviews based on a conference held in Turin, Italy, 10-12 June 2006, showcases the current state of this field and highlights some recent progress in molecular medicine.
Czura
Amy Warenda
AW
Department of Science and Mathematics, Suffolk County Community College Eastern Campus, 121 Speonk-Riverhead Road, Riverhead, NY, USA. cczura@optonline.net
Czura
Christopher J
CJ
D036541:ADP-ribosyl Cyclase / Q000276:immunology*; D051997:ADP-ribosyl Cyclase 1 / Q000276:immunology*; D015703:Antigens, CD / Q000276:immunology*; D020013:Calcium Signaling / Q000276:immunology; D058851:GPI-Linked Proteins; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000276:immunology; D009101:Multiple Myeloma / Q000276:immunology; D009243:NAD / Q000378:metabolism / Q000502:physiology; D011725:Pyridines / Q000378:metabolism; D015398:Signal Transduction
D015703:Antigens, CD; D058851:GPI-Linked Proteins; D011725:Pyridines; D009243:NAD; D036541:ADP-ribosyl Cyclase; C087521:ADP-ribosyl cyclase 2; D051997:ADP-ribosyl Cyclase 1